DD
David Domzalski
President and CEO

David Domzalski insider trades: VYNE Therapeutics (VYNE) stock buys and sales

President and CEO, VYNE Therapeutics Last trade Sep 8, 2020 67 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
13
Open-market trades
since 2018
3
Companies
last trade 2020

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where David reports to the SEC

Open-market buys and sales

13 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 8, 2020VYNE↑ Buy$104K
Jul 1, 2019FOMX↓ Sell$8K
Apr 1, 2019FOMX↓ Sell$19K
Dec 3, 2018FOMX↓ Sell$275
Nov 19, 2018FOMX↓ Sell$20K
Nov 8, 2018FOMX↓ Sell$9K
Oct 1, 2018FOMX↓ Sell$3K
Sep 4, 2018FOMX↓ Sell$380
Aug 8, 2018FOMX↓ Sell$47K
Jul 2, 2018FOMX↓ Sell$3K
Jun 1, 2018FOMX↓ Sell$352
Apr 2, 2018FOMX↓ Sell$3K
Mar 1, 2018FOMX↓ Sell$393

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About David Domzalski's insider trades

David Domzalski is President and CEO at VYNE Therapeutics (VYNE). Since Mar 1, 2018, David has reported 1 open-market purchase worth $104K and 12 sales worth $114K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include shares withheld for taxes (30 filings), grants and awards (25 filings), shares returned to the company (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VYNE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.